The DOI matches its Crossref record.
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
Abstract
Purpose: Apart from localized gastric disease, there is no consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma. The IELSG-19 study (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alone versus chlorambucil plus rituximab in patients not previously given systemic anticancer therapy. Patients and Methods: Patients not responding to or not suitable for local therapy were eligible. In arm A, chlorambucil was given daily 6 mg/m 2 orally (PO) for 6 weeks. Responding patients and those with stable disease continued to be given daily chlorambucil 6 mg/m 2 PO for 14 consecutive days every 28 days for four cycles. In arm B, intravenous rituximab 375 mg/m 2 per day was added on days 1, 8, 15, 22, 56, 84, 112, and 140. After completion of the planned accrual, the protocol was amended to introduce a third arm with rituximab alone. We report the planned final analysis of the first two arms (113 patients in arm A and 114 in arm B). Results: At a median follow-up of 62 months, the 5-year event-free survival (EFS) was significantly better for the patients treated in arm B (68% v 50%; P = .002) who, despite similar overall response rates (90% v 87%), achieved a higher complete remission rate (78% v 65%; P = .025). Progression-free survival was also improved but it did not reach statistical significance (P = .057). Five-year overall survival (OS) was 89% in both arms. Both treatments were well tolerated without unexpected toxicities. Conclusion: Both treatments were active; the better response rate and EFS obtained with the addition of rituximab did not translate into improved OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
Zucca, E., & Bertoni, F. (2016) · Blood · doi:10.1182/blood-2015-12-624304 · Cited by 303
Self-citationTargeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thieblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 298
Self-citationSjögren Syndrome‐associated lymphomas: an update on pathogenesis and management
Nocturne, G., & Mariette, X. (2015) · British Journal of Haematology · doi:10.1111/bjh.13192 · Cited by 295
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“An International Extranodal Lymphoma Study Group trial and a nationwide Spanish trial have established a standard of care with immunochemotherapy for extranodal MZL.(95,96) Moreover, the activities of drugs such as rituximab, everolimus, bortezomib, lenalidomide, and clarithromycin, among others, in MZLs have been add…”
BackgroundSelf-citation
Metadata
- Authors
- Zucca, E., Conconi, A., Laszlo, D., López-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., Vitolo, U., Morschhauser, F., Pileri, S. A., Copie-Bergman, C., Campo, E., Jack, A., Floriani, I., Johnson, P., Martelli, M., Cavalli, F., Martinelli, G., & Thieblemont, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-02-10
- Volume
- 31
- Issue
- 5
- Pages
- 565-572
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163435946
- Cited by
- 229
- References
- 0
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. https://app.cochat.ai/papers/10.1200/jco.2011.40.6272
- The paper
- Zucca, E., Conconi, A., Laszlo, D., López-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., Vitolo, U., Morschhauser, F., Pileri, S. A., Copie-Bergman, C., Campo, E., Jack, A., Floriani, I., Johnson, P., Martelli, M., Cavalli, F., Martinelli, G., & Thieblemont, C. (2013). Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.40.6272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.